Company news
Kalvista Pharmaceuticals, Inc. (NASDAQ:KALV) news
Kalvista Pharmaceuticals, Inc. news releases on 6ix. Latest, Jun 11, 2026: Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Press releases & updates
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
June 11, 2026
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
May 28, 2026
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
April 29, 2026
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
March 29, 2026
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
March 24, 2026
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
March 20, 2026
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
March 17, 2026
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
March 1, 2026
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
February 18, 2026
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 12, 2026
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2026
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
January 7, 2026
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
December 21, 2025
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
November 9, 2025
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
November 5, 2025
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 4, 2025
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
November 2, 2025
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
October 29, 2025
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
October 5, 2025
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer
October 5, 2025
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
October 1, 2025
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
September 25, 2025
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031
September 23, 2025
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes
September 23, 2025
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
September 18, 2025
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results
September 10, 2025
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
September 3, 2025
KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025
August 26, 2025
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union
August 10, 2025
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
July 24, 2025
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
July 14, 2025
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
July 9, 2025
DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetralstat)
July 8, 2025
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
July 7, 2025
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
July 6, 2025
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
June 25, 2025
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
June 15, 2025
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
June 12, 2025
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
June 4, 2025
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
June 1, 2025
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
May 28, 2025
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
May 21, 2025
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
April 29, 2025
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
April 7, 2025
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
March 30, 2025
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
March 24, 2025
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
March 11, 2025
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
March 9, 2025
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
March 2, 2025